Krystal Biotech is a Pennsylvania-based biopharmaceutical company focused on developing and delivering genetic medicines for severe, life-threatening, or rare diseases with limited or no approved therapies. Utilizing a proprietary gene therapy platform, Krystal Biotech aims to address high unmet medical needs with redosable gene therapies. Their first commercial product, VYJUVEK®, is the only redosable gene therapy for treating dystrophic epidermolysis bullosa.
Krystal Biotech has made significant strides in the biopharmaceutical industry, particularly with the launch of VYJUVEK®, marking a milestone in gene therapy for rare disorders. The company's innovative approach and dedication to addressing unmet medical needs have positioned it as a leader in genetic medicine. Their extensive and promising pipeline continues to advance, reflecting their commitment to transforming the lives of patients with debilitating conditions.
